- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05167695
Maintaining Behavior Change: An Evaluation of a Habit-based Sleep Health Intervention
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will test a sleep-health intervention that leverages the science on habit formation. Additionally, the investigators will evaluate whether adding a text messaging intervention improves habit formation. The participants will be 18-30 years old. This is a distinct developmental period in which priorities shift toward self-sufficiency and personal responsibility, which are supported by developing adaptive habits.
Main Aim. To evaluate if adding a text messaging intervention, derived from learning theory, to HABITs improves the utilization of sleep health behavior and improves sleep and circadian outcomes and functioning in the five health-relevant domain outcomes in the short (post-treatment) and longer term (6 and 12-months later), relative to HABITs without text messaging.
Main Hypothesis. Relative to HABITs, youth in HABITs+Texts will (a) establish stronger sleep health behavior habits, (b) report utilizing more sleep health behaviors and (c) exhibit improved sleep and circadian functioning and lower health-relevant risk. These effects will be observed at post-treatment as well as 6 and 12-months later.
Exploratory Aim: To evaluate if the Habit-based Sleep Health Intervention ('HABITs') is associated with an improvement in the utilization of sleep health behavior, an improvement in sleep and circadian outcomes and an improvement in functioning in the five health-relevant domain outcomes in the short (post-treatment) and longer term (6 and 12-months later), relative to baseline.
Exploratory Hypothesis. Combining across the HABITs and HABITs+Texts treatment arms, receiving either intervention will be associated with (a) improved sleep health behavior habits, (b) more utilization of sleep health behaviors, (c) improved sleep and circadian functioning and (d) lower health-relevant risk at post-treatment, 6- and 12-month follow-up, relative to baseline.
Additional exploratory analyses: To examine (a) if sleep health behavior that has become habitual mediates the effects of treatment on improvement in sleep, circadian and health outcomes and (b) if intervention effects are moderated by selected variables (e.g., age, sex, minority group, socioeconomic status (SES), season).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Berkeley, California, United States, 94703
- University of California
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Scoring less than or equal to 26 on the Composite Scale of Morningness OR Mid-point of sleep later than 4:30 AM for 18-24 yo and 3:50 AM for 25-30 yo on work-free/weekend days over the past month OR Night-to-night variation in sleep and wake times across one month of 2 hours or more.
- 'At risk' in one of the five health domains: the emotional domain, the cognitive domain, the behavioral domain, the physical domain and the social domain. "Risk" is defined as scoring 4 or higher on one item from an adapted version of the Work and Social Adjustment Scale.
- Age between 18 and 30.
- English language fluency.
- Able and willing to give informed assent.
- If taking medication for sleep, the dose and frequency of use must have been stable for at least 4 weeks.
Exclusion Criteria:
- Presence of substance abuse/dependence, mental illness, physical illness, suicidality or developmental disorder only if it makes participation in the study unfeasible or if there is a significant risk of harm and/or decompensation if treatment of that comorbid condition is delayed due to participating in this study.
- Evidence of sleep apnea, restless legs or periodic limb movements during sleep. Youth presenting with provisional diagnoses of any of these disorders will be referred for a non-study polysomnography evaluation and will be enrolled only if the diagnosis is disconfirmed or if the disorder is treated.
- Night shifter worker where the shift is scheduled between the hours of midnight to 6am > 2 nights per week.
- Pregnancy or breast-feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Habit-based Sleep Health Intervention (HABITs)
Participants in this condition participate in the HABITs intervention which includes 3x50-minute weekly sessions followed by 6x30-minute weekly sessions. Participants in this group will not receive the texts discussed below. |
A novel low-cost approach derived by leveraging the science of habit formation
|
|
Experimental: Habit-based Sleep Health Intervention plus text messages (HABITs+texts)
Participants in this condition participate in the HABITs intervention which includes 3x50-minute weekly sessions followed by 6x30-minute weekly sessions. Additionally, participants in this group will receive the text messaging intervention. |
A novel low-cost approach derived by leveraging the science of habit formation
In addition to the Habit-based Sleep Health Intervention, the participants will also receive the text messaging intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-Report Automaticity Habits Index integrated with the Utilization Scale
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
16-item; 0-4 scale.
Scores can range from 0 to 64 (Higher score means more automaticity in utilization).
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Utilization Scale
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
16-item; 0-4 scale.
Scores can range from 0 to 64 (Higher score means more utilization).
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Composite Sleep Health Score
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
Composite Sleep Health Score which is defined as the sum of scores on 6 sleep health dimensions: Regularity (Midpoint fluctuation), Satisfaction (Sleep quality question on PROMIS-SD), Alertness (Daytime sleepiness question on PROMIS-SRI), Timing (Mean midpoint), Efficiency (Sleep efficiency) and Duration (Total Sleep Time).
The Sleep Health Composite was constructed such that higher score indicates better sleep health.
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Composite Scale of Morningness
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
Sum of 13-item; Mix of 4-point and 5-point response scale.
Scores can range from 13 (extreme evening) to 55 (extreme morning).
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Patient-Reported Outcomes Measurement Information System - Sleep Related Impairment (PROMIS-SRI)
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
Sum of 8-items rated on a 5-point response scale.
Scores can range from 8 to 40 (Higher score means more Sleep Related impairment)
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Patient-Reported Outcomes Measurement Information System - Sleep Disturbance (PROMIS-SD)
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
Sum of 8-items rated on a 5-point response scale.
Scores can range from 8 to 40 (Higher score means more Sleep Disturbance)
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Adapted version of the Work and Social Adjustment Scale
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
A measure of emotional, cognitive, physical, social and behavioral risk.
The 5 items are each rated on a 0-8 scale.
The 5 individual item scores will be summed into a total score (range: 0 to 40; Higher score means worse outcome).
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pittsburgh Sleep Quality Index
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
19-item.
First four items are integer responses.
The rest of the items are on a 0-3 scale.
Creates 7 composite scores, with the sum of the composite scores ranging from 0 to 21. (Higher score means increased severity of difficulty in all sleep area components).
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Sleep Diary
Time Frame: Baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
(Not a scale); Night-to-night variability in the mid-point of sleep
|
Baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Actigraphy
Time Frame: Baseline to 1-week post treatment
|
(Not a scale); Night-to-night variability in the mid-point of sleep
|
Baseline to 1-week post treatment
|
|
Depression, Anxiety, and Stress Scale (DASS)
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
Three subscales-depression, anxiety, stress-of 7 items each, ranging from 0-3 per item.
Subscale scores range from 0-21.
Final scores are multiplied by two.
Higher scores mean worse outcomes.
Total score will also be calculated.
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Brief Sensation Seeking Scale
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
8-item; 5-point response scale; Scores can range from 8 to 40 (Higher score means higher sensation seeking).
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Physical Health Questionnaire
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
Sum of 15-item, 0-2 response scale.
Scores can range from 0 to 30 (Higher score means worse physical symptoms)
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
PROMIS-Cognitive Function
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
6-item; 1-5 response scale.
Scores can range from 6-30 (Higher score means better cognitive functioning)
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
PROMIS-Ability to participate
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
4-item; 1-5 response scale.
Scores can range from 4-20 (Higher score means better social functioning)
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Ecological Momentary Assessment Composite Risk Score of Functioning - Emotion
Time Frame: Change from baseline to 1-week post treatment
|
(Not a scale) Measured via Ecological Momentary Assessment. a 16-item version of the Positive and Negative Affect Schedule will be administered.
The Positivity Ratio will also be calculated.
|
Change from baseline to 1-week post treatment
|
|
Ecological Momentary Assessment Composite Risk Score of Functioning - Cognitive Domain
Time Frame: Change from baseline to 1-week post treatment
|
(Not a scale) Measured via Ecological Momentary Assessment.
Concentration, distractedness and focus are rated on a 5 point scale.
|
Change from baseline to 1-week post treatment
|
|
Ecological Momentary Assessment (EMA) Composite Risk Score of Functioning - Behavioral Domain
Time Frame: Change from baseline to 1-week post treatment
|
(Not a scale) Measured via Ecological Momentary Assessment.
The investigators assess eating, caffeine, alcohol, nicotine, marijuana, opioids and prescription and over the counter (OTC) stimulants and sleep aids.
Participants will also be asked to list the use of additional psychoactive drugs (e.g.
cocaine).
The investigators tabulate the average weekly frequency and intake of each substance.
|
Change from baseline to 1-week post treatment
|
|
Ecological Momentary Assessment Composite Risk Score of Functioning - Social Domain
Time Frame: Change from baseline to 1-week post treatment
|
(Not a scale) Measured via Ecological Momentary Assessment.
will assess if the participant is with anyone at the time of the call.
Positivity Ratio (see EMA for Emotional Health) will be calculated when the participant is alone, with a family member or with a friend.
|
Change from baseline to 1-week post treatment
|
|
Ecological Momentary Assessment Composite Risk Score of Functioning - Physical Domain
Time Frame: Change from baseline to 1-week post treatment
|
(Not a scale) Measured via Ecological Momentary Assessment.
Physical activity and sedentary behaviors will be assessed.
|
Change from baseline to 1-week post treatment
|
|
Self Report Habit Index: Primary habit bundle to build
Time Frame: At the end of the 2nd through last treatment session, which starts 2 to 3 weeks after the beginning of treatment. Also at 1-week post treatment, 6-month follow-up and 12-month follow-up
|
6 items rated on 1-5 scale.
Scores can range from 1 to 30
|
At the end of the 2nd through last treatment session, which starts 2 to 3 weeks after the beginning of treatment. Also at 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Self Report Habit Index: Primary habit bundle to dismantle
Time Frame: At the end of the 2nd through last treatment session, which starts 2 to 3 weeks after the beginning of treatment. Also at 1-week post treatment, 6-month follow-up and 12-month follow-up
|
6 items rated on 1-5 scale.
Scores can range from 0 to 30
|
At the end of the 2nd through last treatment session, which starts 2 to 3 weeks after the beginning of treatment. Also at 1-week post treatment, 6-month follow-up and 12-month follow-up
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adapted version of the Work and Social Adjustment Scale (individual items)
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
A measure of emotional, cognitive, physical, social and behavioral risk.
The 5 items are each rated on a 0-8 scale.
The 5 individual item scores will be reported separately (range: 0 to 8; Higher score means worse outcome).
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Height
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
(cm)
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Weight
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
Pounds (lbs)
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Hip circumference
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
(cm)
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Waist circumference
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
(cm)
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Sleep Diary
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
(Not a scale); Consensus sleep diary variables, including total sleep time, bedtime, and wake-time, calculated separately for weekdays and weekends.
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Actigraphy
Time Frame: Change from baseline to 1-week post treatment
|
(Not a scale); Sleep parameters, including sleep onset time, sleep offset time, and total sleep time, calculated separately for weekdays and weekends.
|
Change from baseline to 1-week post treatment
|
|
Sussex-Oxford Compassion Scale (SOCS)
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
Sum of 20-item, 5-point response scale. Scores can range from 20 to 100 (Higher score means higher compassion for self). Sub-scale items included. |
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Suicidal Behavior Questionnaire - Revised
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
4-item. Total scores can range from 3-18 (Higher Score means higher Suicidal ideation) Sub-scale items included. |
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Alexian Brothers Urge to Self Injure Scale
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
5-item.
0-6 point scale.
Total scores can range from 0-30 (Higher Score means higher Suicidal ideation)
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
State authenticity
Time Frame: Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
A measure of state authenticity.
The 4 items are each rated on a 1-7 scale.
The sum is averaged (range 1-7; higher scores mean more authenticity)
|
Change from baseline to 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Past month estimates of sleep mid-point workfree days and night-to-night sleep variability
Time Frame: Once at baseline
|
Questions to assess mid-point and night-to-night variability eligibility criteria
|
Once at baseline
|
|
Sleep Medication Log
Time Frame: Once at baseline
|
Questions to assess use of medications
|
Once at baseline
|
|
Credibility Expectancy Questionnaire
Time Frame: After the 2nd treatment session, which is 2 to 3 weeks after the beginning of treatment. Again at the post-treatment assessment which is 1-week post treatment
|
first 3 items are on a 1-9 scale.
The final item is on a 0-100 scale.
(Higher score means the treatment was evaluated as more credible).
|
After the 2nd treatment session, which is 2 to 3 weeks after the beginning of treatment. Again at the post-treatment assessment which is 1-week post treatment
|
|
Adverse Events Checklist
Time Frame: At the 1-week post treatment assessment only
|
16 items to assess adverse events experienced during treatment
|
At the 1-week post treatment assessment only
|
|
Self Report Habit Index: Secondary habit bundle to build
Time Frame: At the end of the 2nd through last treatment session, which starts 2 to 3 weeks after the beginning of treatment. Also at 1-week post treatment, 6-month follow-up and 12-month follow-up
|
1 item rated on 1-5 scale.
Scores can range from 1 to 5
|
At the end of the 2nd through last treatment session, which starts 2 to 3 weeks after the beginning of treatment. Also at 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Self Report Habit Index: Secondary habit bundle to dismantle
Time Frame: At the end of the 2nd through last treatment session, which starts 2 to 3 weeks after the beginning of treatment. Also at 1-week post treatment, 6-month follow-up and 12-month follow-up
|
1 items rated on 1-5 scale.
Scores can range from 1 to 5
|
At the end of the 2nd through last treatment session, which starts 2 to 3 weeks after the beginning of treatment. Also at 1-week post treatment, 6-month follow-up and 12-month follow-up
|
|
Proportion of text messages read
Time Frame: At the 1-week post treatment assessment only
|
1 item rated from 0% to 100%
|
At the 1-week post treatment assessment only
|
|
Script Elicitation Worksheet
Time Frame: After starting treatment, at the end of the 1st through 3rd treatment session (week 1 through week 3 of treatment)
|
(Not a scale); Individualized for each patient, the worksheet includes primary and secondary habit bundles to build and dismantle (e.g., sleep-onset habits, WASO habits, rise-up habits, daytime habits, sleep efficiency habits), and strategy to dismantle primary and secondary habit bundles (e.g., substitution, removing or curtailing, reorganizing)
|
After starting treatment, at the end of the 1st through 3rd treatment session (week 1 through week 3 of treatment)
|
|
Proportion of text message prompts participants responded to
Time Frame: After the third treatment session to the ninth and final treatment session (week 3 to week 8)
|
(Not a scale) Calculated as the number of times a participant responded to a text prompt, divided by the total number of text prompts sent, and multiplied by 100 to produce a percentage from 0% to 100%.
In this trial, the total number of prompts sent to individual participants varied (range: 37 to 105), and the total number of responses from participants ranged from 0 to 76.
|
After the third treatment session to the ninth and final treatment session (week 3 to week 8)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Allison Harvey, PhD, University of California, Berkeley
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-06-14409
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Circadian Dysregulation
-
Stanford UniversityRecruitingCircadian DysregulationUnited States
-
University of California, BerkeleyCompletedCircadian DysregulationUnited States
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)CompletedCircadian DysregulationUnited States
-
Laura Beth KalvasNationwide Children's HospitalRecruitingLight Exposure | Circadian Dysregulation | Pediatric Critical IllnessUnited States
-
VA Palo Alto Health Care SystemSeoul SemiconductorCompletedSleep | Mood | Circadian DysregulationUnited States
-
University of Nebraska LincolnRush University Medical Center; University of NebraskaCompletedObesity | Circadian DysregulationUnited States
-
Northwestern UniversityRush UniversityCompletedPreDiabetes | Circadian DysregulationUnited States
-
Rush University Medical CenterCompletedDelirium | Critical Illness | Circadian DysregulationUnited States
-
TakedaCompletedCircadian DysregulationUnited States
-
University of UtahRecruitingSleep | Sleep Deprivation | Circadian Rhythm | Light Exposure | Insufficient Sleep | Sleep Hygiene | Circadian Dysregulation | Metabolism Changes | Lifestyle Factors | Sleep Hygiene, Inadequate | Circadian MisalignmentUnited States
Clinical Trials on Habit-based Sleep Health Intervention
-
University of Southern DenmarkCompletedPhysical InactivityDenmark
-
Universidad Autónoma de YucatánNot yet recruitingMental Health | Sleep Quality | Students, MedicalMexico
-
VA Office of Research and DevelopmentVA Connecticut Healthcare System; US Department of Veterans AffairsCompleted
-
University of California, Los AngelesNational Institute on Aging (NIA)RecruitingInsomnia ChronicUnited States
-
The Hong Kong Polytechnic UniversityHospital Authority, Hong KongCompleted
-
University of UtahMarquette UniversityCompletedTourette's Disorder | Persistent (Chronic) Motor or Vocal Tic DisorderUnited States
-
Université Catholique de LouvainNot yet recruiting
-
Northwestern UniversityUniversity of Virginia; Tiny Blue Dot FoundationCompletedAnxietyUnited States
-
University of Kansas Medical CenterCompleted
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)TerminatedFatigue | Cancer Survivor | Sleep Disorders | Psychosocial Effects of Cancer and Its TreatmentUnited States